Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efineptakin Alfa and Pembrolizumab in Recurrent Glioblastoma
NCT05465954Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Jan 2023
- Primary completion
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efineptakin alfa and pembrolizumab in glioblastoma (GBM), sponsored by Mayo Clinic. Primary endpoint: Overall Survival Rate at 9 months. Started Jan 2023; status: active, not recruiting.
02
Drugs
efineptakin alfapembrolizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05465954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05465954.